Compare Incyte Corporation (INCY) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Total World Stock Index Fund ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Vanguard Total World Stock Index Fund ETF trades at $161.68. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | VT | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $161.30 |
52-Week Low | $81.61 | $132.19 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
VT trades at $161.53, up 0.35% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The ETF offers global diversification across over 10,000 stocks with a low 0.06% expense ratio, though RSI levels suggest short-term overbought conditions. Recent institutional activity includes mixed positioning changes, such as Barry Investment Advisors reducing holdings by 18.7% in Q2 2026 (SEC filing, August 10, 2026).
Outlook remains positive for long-term investors seeking broad global exposure, supported by VT's cost efficiency and diversification benefits. Risks include trade war uncertainties highlighted in news (The Motley Fool, July 31, 2026) and potential volatility from geopolitical events. Analyst sentiment is generally favorable, with comparisons to peers emphasizing VT's lower fees and comprehensive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
